Plasmapheresis in Clinical Practice

Overview and Mechanism

Plasmapheresis is a therapeutic extracorporeal procedure that mechanically removes circulating antibodies, immune complexes, and pathogenic proteins from plasma, with established efficacy in specific autoimmune and hematologic conditions but requiring careful patient selection and risk-benefit assessment, as recommended by the American Heart Association 1
The procedure involves extracorporeal separation of plasma from cellular blood components through membrane filtration or centrifugation, with blood reconstituted using albumin, fresh-frozen plasma, or crystalloid before reinfusion, according to the American Heart Association 1
Plasma exchange nonselectively removes proteins, while immunoadsorption plasmapheresis selectively targets immunoglobulins, though the latter is less widely available, as noted by the American Heart Association 1

Primary Clinical Indications

Category I: First-Line Therapy

The American Society of Hematology recommends plasmapheresis as the treatment of choice for Thrombotic Thrombocytopenic Purpura (TTP), with daily plasma exchange continued for 14 days or until antibodies become undetectable 2
The American College of Cardiology suggests that plasmapheresis combined with immunosuppression is standard for Cardiac Transplant Antibody-Mediated Rejection (AMR) management 1
In one series of 12 hemodynamically unstable AMR patients treated with plasma exchange plus methylprednisolone, 1-year and 5-year survival were 75% and 51% respectively, as reported by the American College of Cardiology 1

Category II: Adjunctive Therapy with Strong Evidence

The American Society of Nephrology recommends adding plasmapheresis for patients with ANCA-Associated Vasculitis with Severe Renal Disease requiring dialysis or with rapidly increasing serum creatinine 3
The MEPEX trial demonstrated benefit in patients with rapidly progressive glomerulonephritis and serum creatinine ≥5.8 mg/dL, though longer-term analyses have raised questions about sustained benefit, as noted by the American Society of Nephrology 3

Technical Considerations

Procedure Protocols

Standard plasma exchange involves exchanging twice the blood volume, as recommended by the American Heart Association 1
Typical courses range from 2-6 sessions for neurologic conditions to daily exchanges for 5 days in cardiac AMR, according to the American Heart Association 1

Safety Profile and Complications

Mortality and Serious Complications

Overall mortality is estimated at 0.05% based on systematic reviews of >15,500 patients, as reported by the European Respiratory Society 4
Cochrane meta-analysis of 556 Guillain-Barré patients showed plasmapheresis did not increase risk of infection, blood pressure instability, cardiac arrhythmias, or pulmonary embolism, according to the European Respiratory Society 4

Special Population Considerations

Plasmapheresis is well-tolerated in children with neurological disease, with complications that can be anticipated and avoided, though procedural risks are higher than in adults, as noted by the European Respiratory Society 4

Critical Practice Points

When NOT to Use Plasmapheresis

Never as monotherapy for antibody-mediated rejection—always combine with immunosuppression, as recommended by the American College of Cardiology 1
Avoid in dialysis-dependent vasculitis patients without extrarenal manifestations after 3 months of treatment, according to the American Society of Nephrology 3

Monitoring Requirements

Monitor for hemodynamic changes, coagulation abnormalities, and electrolyte imbalances, as recommended by the American Society of Hematology 2
Track disease-specific markers (e.g., GM-CSF antibody titers in aPAP, ADAMTS13 in TTP), according to the European Respiratory Society 4

Plasmapheresis in Clinical Practice: Category II Indications

Adjunctive Therapy with Strong Evidence

The American Society of Nephrology recommends adding plasmapheresis for patients with ANCA-associated vasculitis requiring dialysis or with rapidly increasing serum creatinine, using 60 ml/kg volume replacement, 7-10 treatments total 5, 6, 7
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest discontinuing cyclophosphamide after 3 months in patients who remain dialysis-dependent without extrarenal manifestations 5, 6, 7
For diffuse pulmonary hemorrhage in ANCA vasculitis, initiate plasmapheresis daily until bleeding stops, then every other day for a total of 7-10 treatments 5, 6, 7
The American Academy of Neurology recommends starting IVIG (0.4 g/kg/d for 5 days) or plasmapheresis for severe Guillain-Barré syndrome with self-care limitation, walking impairment, dysphagia, facial weakness, or respiratory muscle weakness 8, 9
For immune checkpoint inhibitor-related myasthenia gravis, permanently discontinue checkpoint inhibitor and initiate IVIG 2 g/kg IV over 5 days or 5-day plasmapheresis course, combining with 1-2 mg/kg methylprednisolone daily 8, 9
The National Comprehensive Cancer Network (NCCN) guidelines suggest administering pulse methylprednisolone 1 g IV daily for 3-5 days plus IVIG 2 g/kg over 5 days for severe or progressing immune checkpoint inhibitor-related encephalitis symptoms with oligoclonal bands 10
Administer rituximab after plasmapheresis, as the procedure removes the drug from circulation, according to the American Journal of Kidney Diseases 11

Plasma Volume Calculation for Plasmapheresis

Primary Calculation Methods

The International Atherosclerosis Society recommends exchanging 1-2 plasma volumes per session, calculated as body weight (kg) × 0.045 L 12
Plasma volume can be calculated as 45 mL/kg of body weight (or 0.045 L/kg), which is the most widely used clinical approximation 12
Plasma volume can also be derived from total blood volume using the formula: Plasma Volume = Blood Volume / (1 - Hematocrit) 12

Volume Replacement Protocols by Indication

For ANCA-Associated Vasculitis, use 60 mL/kg volume replacement for patients with severe renal disease or diffuse pulmonary hemorrhage 13
For Hyperviscosity Syndrome (Multiple Myeloma, Waldenström's), replace approximately two-thirds of the patient's plasma volume (typically 3-4 liters in adults) 14, 15
For Lipoprotein Apheresis (Familial Hypercholesterolemia), process 1-2 plasma volumes calculated as body weight (kg) × 0.045 L 12

Replacement Fluid Selection

5% albumin solution is the most common replacement fluid for most indications 14, 15

Critical Pitfalls to Avoid

Do not use fixed volumes without weight-based calculation—plasma volume varies significantly with body size 12
Do not use plasma exchange as monotherapy—always combine with definitive treatment (immunosuppression, chemotherapy) as the procedure only provides temporary removal of pathogenic substances 14, 15

High Volume Plasmapheresis Recommendations

Volume Replacement Guidelines

The American Society of Nephrology recommends using 60 mL/kg volume replacement for high volume plasmapheresis, which represents approximately 1.3 times the standard plasma volume calculation of 45 mL/kg, for patients with severe renal disease, such as ANCA-associated vasculitis 16
For cardiac transplant antibody-mediated rejection, the American Heart Association recommends exchanging 1-2 plasma volumes, with a standard calculation of body weight (kg) × 0.045 L (or 45 mL/kg), and performing 4-5 sessions over 10-14 days 17, 18

Treatment Protocols

For ANCA-associated vasculitis with severe renal disease, the American College of Rheumatology recommends performing 7-10 high volume plasmapheresis treatments, with 60 mL/kg volume replacement, and initiating daily treatments for diffuse pulmonary hemorrhage until bleeding stops, then every other day 16
For cardiac transplant antibody-mediated rejection, some centers use daily or every other day plasmapheresis for a minimum of 5 sessions, with exchange of 1-2 plasma volumes 18

Plasma Exchange Protocol Considerations

Technical Procedure Details

The British Medical Journal recommends that plasma exchange requires high blood flow rates, necessitating either peripheral venous access with large-bore catheters or central venous access, which may cause discomfort and increase infection, clotting, or bleeding risk 19, 20
The British Medical Journal notes that plasma exchange nonselectively removes proteins and may affect pharmacokinetics of medications, and that rituximab should be administered after plasma exchange, as the procedure removes the drug from circulation 19

Institutional Variability

The British Medical Journal reports that protocols for plasma exchange vary largely between medical institutions, and there is significant heterogeneity in plasma exchange protocols, with access potentially limited in some jurisdictions and costs not covered by medical insurance 19, 20

Plasmapheresis and IVIG Administration Guidelines

Introduction to Plasmapheresis and IVIG

Plasmapheresis nonselectively removes all plasma proteins, including immunoglobulins, which is why IVIG must always be administered after plasmapheresis is completed 21
The American Heart Association recommends plasmapheresis as a treatment for certain conditions, and notes that IVIG should be administered after the procedure to avoid removal of the immunoglobulins 21

Mechanism of Removal

Plasmapheresis removes all plasma proteins, including immunoglobulins (IgG, IgM, IgA), through extracorporeal separation of plasma from cellular blood components via membrane filtration or centrifugation 21, 22, 23
Immunoadsorption plasmapheresis is specifically designed to remove only immunoglobulins, making it even more efficient at removing IVIG 21, 22, 23

Clinical Protocols

The standard protocol is to give IVIG 2 g/kg divided into doses after the final plasmapheresis session, typically administered over 2 consecutive days, as recommended by the American College of Cardiology 24, 25
Multiple centers use sequential plasmapheresis followed by IVIG, with the Stanford protocol specifying plasmapheresis daily or every other day for a minimum of 5 sessions, and IVIG 2 g/kg divided over days 1-2 and days 29-30 (after plasmapheresis completion) 24

Treatment Sequencing

Initiate plasmapheresis first, typically 4-7 sessions over 7-14 days, and complete the full plasmapheresis course before administering therapeutic IVIG, as recommended by the American Society of Nephrology 21, 24
Administer IVIG 2 g/kg divided over 2 days after the final plasmapheresis session, with a strength of evidence level of IIa, as recommended by the American College of Cardiology 24, 25